Keeping You Updated
Here is a selection of recent PharmaVentures press releases...
Essential Training an Ingredient to Success
In response to growing industry demand, PharmaVentures, a leading provider of specialist consultancy and intelligence services, has launched a series of training programmes to provide business executives from across the world with the essential skills necessary to manage and negotiate multi-million dollar agreements.
Pfizer - Wyeth: Good Deal – Bad Deal?
If Pfizer and Wyeth merge to create a $60 billion company, will it be a good deal or a bad deal? Fintan Walton, PhD, CEO of PharmaVentures, says, ‘This is potentially a bad deal for both companies. By 2012, the merged company will have lost $25bn with products coming off-patent with the current pipeline only replenishing $2.5bn in that time’.
PharmaVentures Helps Deal-Making Through Beta Launch Of Its PharmaDeals® v2 Database
PharmaVentures, the transaction advisory and media company, announced today the launch of its new product, PharmaDeals v2, a database of deals and alliances for the pharmaceuticals sector.
PharmaVentures and Growthink Research Join Forces to Deliver Bioscience Industry Information Solutions
PharmaVentures announced today an agreement with Growthink Research, the U.S.-based market research firm, to distribute its Venture Capital database to customers in industry and academic institutions worldwide.